Education
About Us
Working with TipRanks
Follow Us
ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
AVBP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$15.47 - $36.37
Previous CloseN/A
Volume49.09K
Average Volume (3M)271.38K
Market Cap
$775.68M
Enterprise Value$526.49M
Total Cash (Recent Filing)$235.69M
Total Debt (Recent Filing)$98.00K
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Nov 13, 2025EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding40,568,943
10 Day Avg. Volume198,602
30 Day Avg. Volume271,383
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.60
Forecast
1Y Price Target
$39.38Price Target Upside98.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe FAVOUR trial showed that firmonertinib achieved a high objective response rate in treatment-naïve and pretreated patients, which compares favorably to competitor agents.
Financial PositionThe cash position is strong, with approximately $335.6 million, providing a solid financial foundation for ongoing and future projects.
ValuationValuation models suggest a price target of $45, with firmonertinib contributing significantly to the share value, reflecting confidence in the drug's potential.
Bears Say
Financial PerformanceArriVent reported a net loss wider than previously forecasted, with increased R&D and SG&A expenses.
Short InterestShort Interest (% Float) is 27.9%.
Stock DilutionThe target price has been updated to $33 due to approximately 18% dilution from the public.
AVBP FAQ
What was ArriVent BioPharma, Inc.’s price range in the past 12 months?
ArriVent BioPharma, Inc. lowest stock price was $15.47 and its highest was $36.37 in the past 12 months.
What is ArriVent BioPharma, Inc.’s market cap?
ArriVent BioPharma, Inc.’s market cap is $775.68M.
When is ArriVent BioPharma, Inc.’s upcoming earnings report date?
ArriVent BioPharma, Inc.’s upcoming earnings report date is Nov 13, 2025 which is in 71 days.
How were ArriVent BioPharma, Inc.’s earnings last quarter?
ArriVent BioPharma, Inc. released its earnings results on Aug 11, 2025. The company reported -$0.9 earnings per share for the quarter, missing the consensus estimate of -$0.712 by -$0.188.
Is ArriVent BioPharma, Inc. overvalued?
According to Wall Street analysts ArriVent BioPharma, Inc.’s price is currently Undervalued.
Does ArriVent BioPharma, Inc. pay dividends?
ArriVent BioPharma, Inc. does not currently pay dividends.
What is ArriVent BioPharma, Inc.’s EPS estimate?
ArriVent BioPharma, Inc.’s EPS estimate is -0.79.
How many shares outstanding does ArriVent BioPharma, Inc. have?
ArriVent BioPharma, Inc. has 40,568,943 shares outstanding.
What happened to ArriVent BioPharma, Inc.’s price movement after its last earnings report?
ArriVent BioPharma, Inc. reported an EPS of -$0.9 in its last earnings report, missing expectations of -$0.712. Following the earnings report the stock price went down -3.335%.
Which hedge fund is a major shareholder of ArriVent BioPharma, Inc.?
Currently, no hedge funds are holding shares in AVBP
ArriVent BioPharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.38 (98.49% Upside)
$39.38 (98.49% Upside)
Hedge Fund Trend
Increased
By 6.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.77%
12-Months-Change
Fundamentals
Return on Equity
-50.13%
Trailing 12-Months
Asset Growth
-12.74%
Trailing 12-Months
Company Description
ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
AVBP Stock 12 Month Forecast
Average Price Target
$39.38
▲(98.49% Upside)
Technical Analysis
Arbutus Biopharma
―
Xencor
―
Rocket Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―
Ownership Overview
1.53% Insiders
12.39% Mutual Funds
4.39% Other Institutional Investors
72.34% Public Companies and
Individual Investors